Intravenous AAV9- ATP7A plus subcutaneous copper histidinate optimizes outcomes in a lethal Menkes disease mouse model
Science Advances · 2025
DOI: 10.1126/sciadv.adw5612 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, 2025. Verfasst von Lalitha Venkataraman und 6 weiteren Autor:innen. Beteiligte Einrichtung: Center for Gene Therapy, Nationwide Children's Hospital, Columbus, OH 43205, USA. Hauptthemen laut MEDLINE: Menkes Kinky Hair Syndrome, Copper-Transporting ATPases, Dependovirus, Copper. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NINDS NIH HHS, Intramural NIH HHS.
Abstract (Originalsprache)
Menkes disease is an X-linked recessive condition characterized by seizures, failure to thrive, and rapid, progressive neurodegeneration beginning within weeks after birth. Death usually occurs by 3 years of age. The disorder is caused by genetic variants in ATP7A , an evolutionarily conserved copper transporter that is crucial for normal brain development. The mottled-brindled mouse recapitulates salient features of the human illness. Affected male mice typically die by 14 postnatal days. We evaluated a single-dose intravenous adeno-associated virus gene therapy approach to deliver working copies of a codon-optimized version of ATP7A to male mottled-brindled mice. In conjunction with subcutaneous injections of clinical-grade copper histidinate in the first month of life, 95% long-term survival was attained, which was correlated with improvements in serum and brain copper levels, brain neurochemical profiles, somatic growth, and neuromotor function. The notable results support a trial of this treatment combination in affected male newborns with Menkes disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Center for Gene Therapy, Nationwide Children's Hospital, Columbus, OH 43205, USA.
- Department of Pediatrics, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA.
- Autonomic Medicine Section, Clinical Neurosciences Program, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD 20892, USA.
ORCID-Profile: Lalitha Venkataraman, Christopher J Jeanty, Tarun Kaniganti, Patricia Sullivan, David S Goldstein, Stephen G Kaler
Förderung
- NINDS NIH HHS
- Intramural NIH HHS
Zitieren
APA
Venkataraman, L., Jeanty, C. J., Kaniganti, T., Kennedy, B. J., Sullivan, P., Goldstein, D. S., & Kaler, S. G. (2025). Intravenous AAV9- ATP7A plus subcutaneous copper histidinate optimizes outcomes in a lethal Menkes disease mouse model. Science Advances. https://doi.org/10.1126/sciadv.adw5612
Vancouver
Venkataraman L, Jeanty CJ, Kaniganti T, Kennedy BJ, Sullivan P, Goldstein DS, et al. Intravenous AAV9- ATP7A plus subcutaneous copper histidinate optimizes outcomes in a lethal Menkes disease mouse model. Science Advances. 2025. doi:10.1126/sciadv.adw5612
BibTeX
@article{Venkataraman2025,
author = {Venkataraman, Lalitha and Jeanty, Christopher J and Kaniganti, Tarun and Kennedy, Benjamin J and Sullivan, Patricia and Goldstein, David S and Kaler, Stephen G},
title = {Intravenous AAV9- ATP7A plus subcutaneous copper histidinate optimizes outcomes in a lethal Menkes disease mouse model},
journal = {Science Advances},
year = {2025},
doi = {10.1126/sciadv.adw5612}
}
EUVIMED